Ridgetech Inc (RDGT) — Titan Protect Analysis

RDGT

Ridgetech Inc

Healthcare · ·

$1.41

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2M

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

-11.7%

Year-over-year revenue change

Profit Margin

10.4%

How much profit the company keeps from each dollar of revenue

ROE

-8.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Ridgetech Inc

Ridgetech, Inc. operates as a wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. It operates through three segments: Retail Drugstores, Online Pharmacy, and Drug Wholesale. The company engages in offline and online wholesale distribution of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as

https://www.ridgetch.com

Country: China Employees: 61 Industry: Pharmaceutical Retailers

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.411

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1170

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.937

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-93.5%

Historical annualised return based on price data

Max Drawdown

-99.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.34

Very low correlation to market moves

52W High

$760.50

100% below the year high

52W Low

$1.21

17% above the year low

Avg Volume

584,357

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-54.61

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

15.65

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

3.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-0.1%

Profit from core operations before interest and tax

Free Cash Flow

$6M

Positive — the business generates more cash than it spends

Revenue (TTM)

$120M

Total revenue over the last 12 months

Net Income

$-2,006,486

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go